Dr. Amy L. Mahan

AMY MAHAN is a scientist and a patent litigator whose extensive trial experience shapes how she advises life sciences companies across the product life cycle. She helps clients evaluate patent risk, strengthen their positions, and navigate disputes with an understanding of how their patents, agreements, and technical positions could be tested in court, whether litigation is years away or already underway.

Amy holds a Ph.D. in neuroscience; her research is focused on molecular biology, gene editing, and synaptic plasticity, as well as on hands-on training in gene expression, cell biology, and protein engineering. She is also registered to practice before the U.S. Patent and Trademark Office. That background enables her to work directly with scientists and experts to develop case strategy; translate complex technical issues into clear, practical advice for legal and business teams; and present the science persuasively to judges and juries.

Her experience includes:

• Representing clients in biologics and protein therapeutics disputes at trial, on appeal, and before the Patent Trial and Appeal Board (PTAB), including matters involving antibody and protein genus claims, subcutaneous delivery technologies, and cell therapy.
• Arbitrating and mediating patent licensing disputes involving biologics portfolios and gene therapy technology.
• Litigating small-molecule patent cases, including Hatch-Waxman and innovator-versus-innovator disputes, through trial and Federal Circuit appeals.
• Advising cell therapy and stem cell companies on patent landscapes, portfolio and claiming strategy, license and collaboration agreements, and IP diligence, including on a stem cell platform acquisition.
• Representing technology companies in patent litigation in district court, at the PTAB, and before the Federal Circuit, in software, fintech, medical devices, and semiconductor chips.

Amy has litigated in the District of Delaware, the Eastern District of Texas, and the Central and Northern Districts of California, as well as before the PTAB and the Federal Circuit.

Amy has been recognized by Best Lawyers: Ones to Watch® in America for Litigation —Intellectual Property (2026–2027). In 2025, she and her team were also named “Litigators of the Week” by The American Lawyer’s Litigation Daily.